166 related articles for article (PubMed ID: 34130846)
1. Imaging After Locoregional Therapy for Hepatocellular Carcinoma with Emphasis on LIRADS Treatment Response Assessment Criteria.
Bajaj G; Sundaram K; Jambhekar K; Ram R
Semin Ultrasound CT MR; 2021 Aug; 42(4):318-331. PubMed ID: 34130846
[TBL] [Abstract][Full Text] [Related]
2. Imaging After Locoregional Therapy for Hepatocellular Carcinoma With Emphasis on LIRADS Treatment Response Assessment Criteria.
Bajaj G; Sundaram K; Jambhekar K; Ram R
Semin Ultrasound CT MR; 2021 Aug; 42(4):390-404. PubMed ID: 34130851
[TBL] [Abstract][Full Text] [Related]
3. Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm.
Kielar A; Fowler KJ; Lewis S; Yaghmai V; Miller FH; Yarmohammadi H; Kim C; Chernyak V; Yokoo T; Meyer J; Newton I; Do RK
Abdom Radiol (NY); 2018 Jan; 43(1):218-230. PubMed ID: 28780679
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of LI-RADS Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma in Liver Transplant Candidates: Intraindividual Comparison between CT and Hepatobiliary Agent-enhanced MRI.
Bae JS; Lee JM; Yoon JH; Kang HJ; Jeon SK; Joo I; Lee KB; Kim H
Radiology; 2021 May; 299(2):336-345. PubMed ID: 33650901
[TBL] [Abstract][Full Text] [Related]
5. Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review.
Voizard N; Cerny M; Assad A; Billiard JS; Olivié D; Perreault P; Kielar A; Do RKG; Yokoo T; Sirlin CB; Tang A
Insights Imaging; 2019 Dec; 10(1):121. PubMed ID: 31853668
[TBL] [Abstract][Full Text] [Related]
6. LI-RADS treatment response lexicon: review, refresh and resolve with emerging data.
Ram R; Kampalath R; Shenoy-Bhangle AS; Arora S; Kielar AZ; Mendiratta-Lala M
Abdom Radiol (NY); 2021 Aug; 46(8):3549-3557. PubMed ID: 34106301
[TBL] [Abstract][Full Text] [Related]
7. LI-RADS: Past, Present, and Future, From the
Marks RM; Masch WR; Chernyak V
AJR Am J Roentgenol; 2021 Feb; 216(2):295-304. PubMed ID: 33052720
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Hepatocellular Carcinoma Treatment Response After Locoregional Therapy.
Kampalath R; Tran-Harding K; Do RKG; Mendiratta-Lala M; Yaghmai V
Magn Reson Imaging Clin N Am; 2021 Aug; 29(3):389-403. PubMed ID: 34243925
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.
Seo N; Kim MS; Park MS; Choi JY; Do RKG; Han K; Kim MJ
Eur Radiol; 2020 Jan; 30(1):261-271. PubMed ID: 31418085
[TBL] [Abstract][Full Text] [Related]
10. Artificial intelligence in assessment of hepatocellular carcinoma treatment response.
Spieler B; Sabottke C; Moawad AW; Gabr AM; Bashir MR; Do RKG; Yaghmai V; Rozenberg R; Gerena M; Yacoub J; Elsayes KM
Abdom Radiol (NY); 2021 Aug; 46(8):3660-3671. PubMed ID: 33786653
[TBL] [Abstract][Full Text] [Related]
11. Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents.
Aslam A; Kamath A; Spieler B; Maschiocchi M; Sabottke CF; Chernyak V; Lewis SC
Abdom Radiol (NY); 2021 Aug; 46(8):3565-3578. PubMed ID: 33856509
[TBL] [Abstract][Full Text] [Related]
12. Interobserver and intermodality agreement of standardized algorithms for non-invasive diagnosis of hepatocellular carcinoma in high-risk patients: CEUS-LI-RADS versus MRI-LI-RADS.
Schellhaas B; Hammon M; Strobel D; Pfeifer L; Kielisch C; Goertz RS; Cavallaro A; Janka R; Neurath MF; Uder M; Seuss H
Eur Radiol; 2018 Oct; 28(10):4254-4264. PubMed ID: 29675659
[TBL] [Abstract][Full Text] [Related]
13. LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents.
Santillan C; Fowler K; Kono Y; Chernyak V
Abdom Radiol (NY); 2018 Jan; 43(1):75-81. PubMed ID: 28828680
[TBL] [Abstract][Full Text] [Related]
14. Liver imaging reporting and data system (LI-RADS) version 2014: understanding and application of the diagnostic algorithm.
An C; Rakhmonova G; Choi JY; Kim MJ
Clin Mol Hepatol; 2016 Jun; 22(2):296-307. PubMed ID: 27304548
[TBL] [Abstract][Full Text] [Related]
15. LI-RADS treatment response assessment of combination locoregional therapy for HCC.
Gerena M; Molvar C; Masciocchi M; Nandwana S; Sabottke C; Spieler B; Sharma R; Tsai L; Kielar A
Abdom Radiol (NY); 2021 Aug; 46(8):3634-3647. PubMed ID: 34120207
[TBL] [Abstract][Full Text] [Related]
16. Up-to-Date Role of Liver Imaging Reporting and Data System in Hepatocellular Carcinoma.
Chernyak V
Surg Oncol Clin N Am; 2024 Jan; 33(1):59-72. PubMed ID: 37945145
[TBL] [Abstract][Full Text] [Related]
17. Role of the radiologist at HCC multidisciplinary conference and use of the LR-TR algorithm for improving workflow.
Shenoy-Bhangle AS; Tsai LL; Masciocchi M; Arora SS; Kielar AZ
Abdom Radiol (NY); 2021 Aug; 46(8):3558-3564. PubMed ID: 33904990
[TBL] [Abstract][Full Text] [Related]
18. Imaging diagnosis of hepatocellular carcinoma: LI-RADS.
Cunha GM; Sirlin CB; Fowler KJ
Chin Clin Oncol; 2021 Feb; 10(1):3. PubMed ID: 32527115
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018.
Ludwig DR; Fraum TJ; Cannella R; Ballard DH; Tsai R; Naeem M; LeBlanc M; Salter A; Tsung A; Shetty AS; Borhani AA; Furlan A; Fowler KJ
Abdom Radiol (NY); 2019 Jun; 44(6):2116-2132. PubMed ID: 30798397
[TBL] [Abstract][Full Text] [Related]
20. Liver Imaging Reporting and Data System Version 2018: What Radiologists Need to Know.
Abdel Razek AAK; El-Serougy LG; Saleh GA; Shabana W; Abd El-Wahab R
J Comput Assist Tomogr; 2020; 44(2):168-177. PubMed ID: 32195795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
